Gout, beyond the joint : How should we treat it?
Copyright © 2023 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved..
Gout is a disease caused by the chronic deposition of monosodium urate crystals. Its clinical presentation as an acute, self-limiting arthritis and the belief that it is a banal, self-inflicted disease have led to its poor management. Despite advances in the knowledge of the disease and the simplicity of its management, no more than 30% of patients are well treated. In Spain, the prevalence of gout is 2.5% and its incidence is increasing. In the following article we will review the pathogenesis of gout and hyperuricaemia, highlighting the greater weight of genetics and renal function over diet. We will look at the consequences of crystal deposition. Gout, in addition to its joint presentation and renal involvement, has been shown to be an independent cardiovascular risk factor. Hypouricemic therapy is the most important treatment, as it is the one that dissolves the crystals and cures the disease. This requires the sustained achievement of uricemia levels below 6mg/dl. We will also review preventive and flares treatment, as well as the role of patient education in terms of both lifestyle and dietary habits and adherence to pharmacological treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:50 |
|---|---|
| Enthalten in: |
Semergen - 50(2024), 5 vom: 31. Jan., Seite 102176 |
| Sprache: |
Spanisch |
|---|
| Weiterer Titel: |
La gota, más allá de la articulación: ¿cómo debemos tratarla? |
|---|
| Beteiligte Personen: |
Pou, M A [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Ácido úrico |
|---|
| Anmerkungen: |
Date Revised 01.02.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.1016/j.semerg.2023.102176 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM367907666 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM367907666 | ||
| 003 | DE-627 | ||
| 005 | 20240202232300.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240202s2024 xx |||||o 00| ||spa c | ||
| 024 | 7 | |a 10.1016/j.semerg.2023.102176 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1278.xml |
| 035 | |a (DE-627)NLM367907666 | ||
| 035 | |a (NLM)38301402 | ||
| 035 | |a (PII)S1138-3593(23)00256-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a spa | ||
| 100 | 1 | |a Pou, M A |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gout, beyond the joint |b How should we treat it? |
| 246 | 3 | 3 | |a La gota, más allá de la articulación: ¿cómo debemos tratarla? |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 01.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a Copyright © 2023 Sociedad Española de Médicos de Atención Primaria (SEMERGEN). Publicado por Elsevier España, S.L.U. All rights reserved. | ||
| 520 | |a Gout is a disease caused by the chronic deposition of monosodium urate crystals. Its clinical presentation as an acute, self-limiting arthritis and the belief that it is a banal, self-inflicted disease have led to its poor management. Despite advances in the knowledge of the disease and the simplicity of its management, no more than 30% of patients are well treated. In Spain, the prevalence of gout is 2.5% and its incidence is increasing. In the following article we will review the pathogenesis of gout and hyperuricaemia, highlighting the greater weight of genetics and renal function over diet. We will look at the consequences of crystal deposition. Gout, in addition to its joint presentation and renal involvement, has been shown to be an independent cardiovascular risk factor. Hypouricemic therapy is the most important treatment, as it is the one that dissolves the crystals and cures the disease. This requires the sustained achievement of uricemia levels below 6mg/dl. We will also review preventive and flares treatment, as well as the role of patient education in terms of both lifestyle and dietary habits and adherence to pharmacological treatment | ||
| 650 | 4 | |a English Abstract | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Allopurinol | |
| 650 | 4 | |a Alopurinol | |
| 650 | 4 | |a Atención primaria | |
| 650 | 4 | |a Febuxostat | |
| 650 | 4 | |a Gota | |
| 650 | 4 | |a Gout | |
| 650 | 4 | |a Hiperuricemia | |
| 650 | 4 | |a Hyperuricemia | |
| 650 | 4 | |a Primary health care | |
| 650 | 4 | |a Uric acid | |
| 650 | 4 | |a Ácido úrico | |
| 700 | 1 | |a Martinez-Laguna, D |e verfasserin |4 aut | |
| 700 | 1 | |a Diaz-Torne, C |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Semergen |d 1998 |g 50(2024), 5 vom: 31. Jan., Seite 102176 |w (DE-627)NLM095511652 |x 1578-8865 |7 nnns |
| 773 | 1 | 8 | |g volume:50 |g year:2024 |g number:5 |g day:31 |g month:01 |g pages:102176 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.semerg.2023.102176 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 50 |j 2024 |e 5 |b 31 |c 01 |h 102176 | ||